• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

10.55 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sagimet Biosciences Inc. - Series A Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data ↗
Today 4:01 EDT
Sagimet Biosciences (NASDAQ:SGMT) plans to begin a Phase III study of its oral fatty acid synthase, or FASN, inhibitor denifanstat in moderate-to-severe acne within the next several months, following... 
Via MarketBeat
News headline image
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
August 13, 2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the U.S. on track to initiate in second half of 2026 
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
August 11, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
August 04, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes
June 29, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
May 27, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 13, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 12, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
May 11, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
Unusual volume stocks are being observed in Tuesday's session. ↗
April 28, 2026
Via Chartmill
These stocks are moving in today's session ↗
April 27, 2026
Via Chartmill
Top stock movements in today's session. ↗
April 27, 2026
Via Chartmill
News headline image
Why Sagimet Biosciences Stock Is Soaring Today ↗
April 27, 2026
The biopharma company confirmed it's still aiming at the United States' acne-treatment market. 
Via The Motley Fool
These stocks are gapping in today's session ↗
April 27, 2026
Via Chartmill
Top movers in Monday's pre-market session ↗
April 27, 2026
Via Chartmill
News headline image
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
April 27, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Provides Strategic and Corporate Updates
April 27, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
April 20, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
March 11, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
February 25, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
February 05, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tuesday's session: gap up and gap down stocks ↗
February 03, 2026
Via Chartmill
News headline image
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
February 02, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
January 08, 2026
Via Chartmill
News headline image
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
January 08, 2026
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
December 18, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
December 17, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
December 10, 2025
From Sagimet Biosciences Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap